Cancer clinical trials in the region Nouvelle-Aquitaine
454 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Acute leukemia
#NCT04065399
#2020-004104-34
Phase 2, Cohorte 2A
Required histologic types
Acute lymphoblastic leukemia (ALL)
Other acute leukemia
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2
Acute leukemia
#NCT04065399
#2020-004104-34
Phase 2, Cohorte 2B
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
KMT2A
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2
Acute leukemia
#NCT04065399
#2020-004104-34
Phase 2, Cohorte 2D
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
Other mutation
KMT2A
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2
Acute leukemia
#NCT04065399
#2020-004104-34
Phase 2, Cohorte 2C
Required histologic types
Acute myeloid leukemia (AML)
Required central nervous system lesions
None
Treated / Controled
Required genetic anomalies
NPM1
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
3 recruiting sites
Syndax Pharmaceuticals
Phase 1 / Phase 2
Lymphoma
CLL & Richter's syndrome
Acute leukemia
#NCT04707300
#2019-004883-23
Required histologic types
CLL (Chronic Lymphocytic Leukemia)
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
4 recruiting sites
Assistance Publique - Hôpitaux de Paris
Phase 1 / Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT07232602
#2025-522253-19-00
Required histologic types
Invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 1 / Phase 2
Prostate cancer
#NCT07258407
#2025-523273-41-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
T.O.A.D. Oncology SA
Phase 1 / Phase 2
Lung cancer
Prostate cancer
Stomach and esophageal cancer
#NCT05434234
Required histologic types
SCLC (Small Cell Lung Cancer)
NSCLC (Non-Small Cell Lung Cancer)
Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06265727
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Corbus Pharmaceuticals Inc.
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT05410145
#2023-508517-16-00
Required disease stage
Locally Advanced
Metastatic
Metastatic Castration-resistant
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
D3 Bio (Wuxi) Co., Ltd